Join
Live feed
·
PRReleasevia Quantisnow
60 Degrees Pharmaceuticals Inc. logo

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

ByQuantisnow·Wall Street's wire, on your screen.
SXTP· 60 Degrees Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SXTP (60 Degrees Pharmaceuticals Inc.) and more on Quantisnow.